Their a state-of-the-art wearable device monitors a COPD patient’s respiration while being completely unobtrusive and portable, leading to 94% compliance by the user.
MAIA Biotechnology received preliminary data from its Phase 2 Clinical trial and the results are very promising.
Kineta, Inc. (Nasdaq: KA), announced today the achievement of a development milestone which triggers a $5 million payment from its research and development collaboration with Merck
Veralox has begun Phase 2 clinical trials for a new treatment for HIT with a market potential of more than $850M.
Spire Health has been working with Stanford University and the NIH to create an FDA-approved remote patient monitoring system that reduces hospitalizations for COPD by 65%.
The Lumicell Direct Visualization System assists surgeons to detect cancerous tissue in real time so they can remove it all the first time.
Kineta, Inc. (Nasdaq: KA), announced today the achievement of a development milestone which triggers a $5 million payment from its research and development collaboration with Merck
Join our fireside chat to get a physician’s perspective on pain management and the effect on patients when they are introduced to opioids
Spire Health’s remote respiratory monitoring system reduces hospitalizations 65% and saves payers $10,000 per member annually
bit.bio has the ability to create any human cell type and to manufacture it at scale with precision and consistency
1460 Broadway
New York, NY 10036
(917) 747-6198
© Copyright 2023 FORCE Family Office
